

# Abstract from AroCell has been accepted for presentation in a Poster Session at the AACR Annual Meeting 2020

**An abstract from AroCell has been accepted for poster presentation on the American Association of Cancer Research 2020 (AACR 2020) held April 24-29 in San Diego, California, USA.**

The abstract is entitled "Evaluation of TK1 protein changes using the AroCell TK 210 ELISA in an acute myeloid leukemia (AML) xenograft model during 5-fluorouracil treatment." by Jagarlamudi KK. The study describes the utility of TK1 protein levels by AroCell TK 210 ELISA to monitor the changes in AML xenograft mouse model during 5-fluorouracil treatment.

The abstract will be online on the AACR Online Itinerary on Tuesday, March 24, 2020.

## Contacts

---

Michael Brobjer, CEO  
Telephone: +46(0)18 50 30 20  
E-mail: [michael.brobjer@arocell.com](mailto:michael.brobjer@arocell.com)

## About Thymidine Kinase 1

---

Thymidine Kinase 1 (TK1) is a key enzyme in DNA precursor synthesis. It is upregulated during the late G1 phase and early S phase of the cell cycle and its presence in cells is an indicator of active cell proliferation. Increased levels of TK1 in the blood can indicate active cell proliferation as a consequence of abnormal cell turnover and cell disruption triggered by for example therapeutic agents.

## About TK 210 ELISA

---

AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. The ELISA format is simple and robust, requires no special instrumentation to perform and can easily be incorporated into standard laboratory processes. By utilizing monoclonal antibodies specific for the TK1 epitope TK 210, AroCell TK 210 ELISA brings improved sensitivity and specificity to the assay of this key biomarker. AroCell TK 210 ELISA provides new opportunities for studying cellular proliferation, disruption, and monitoring of therapy response and relapse in subjects with haematological and solid tumours.

## About AroCell

---

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: [Certifiedadviser@redeye.se](mailto:Certifiedadviser@redeye.se), +46 (0)8 121 576 90. For more information; [www.arocell.com](http://www.arocell.com)

## Attachments

---

[Abstract from AroCell has been accepted for presentation in a Poster Session at the AACR Annual Meeting 2020](#)